AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer

NCT ID: NCT02380443

Last Updated: 2025-05-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-09-30
• Study Completion Date: 2018-09-30

Brief Summary

This is a single center, open label dose frequency escalation study of CryoVax®. personalized anti-tumor vaccine protocol combining the cryoablation of a selected metastatic lesion with intra-lesional immunotherapy with AlloStim®. The in-situ (in the body) cancer vaccine step combines killing a single metastatic tumor lesion by use of cryoablation in order to cause the release of tumor-specific markers to the immune system and then injecting bioengineered allogeneic immune cells (AlloStim®) into the lesion as an adjuvant in order to modulate the immune response and educate the immune system to kill other tumor cells where ever they reside in the body.

Detailed Description

Colorectal cancer (CRC) ranks as the third most common cancer worldwide. Metastasis is the main reason of death in CRC patients. The current drugs used to treat colorectal cancer provide important treatment options for patients, their limitations including drug resistance, poor efficacy and severe side effects. Development of new therapeutic strategies for KRAS mutant as well as BRAF mutant tumors are therefore highly needed in order to offer a new category of drug (immunotherapy). This study targets the population of mCRC patients that have progressed after two lines of chemotherapy and are not eligible for targeted therapies.

Conditions

Colorectal Cancer Metastatic

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dosing Schedule A (with cryoablation)

• The priming step with ID injections of AlloStim on Days 0, 7, and 14
• The vaccination step with cryoablation and IT (intratumoral) injection of AlloStim on Day 21
• The activation step with IV infusion of AlloStim on Day 28
• The booster step with two IV booster infusions of AlloStim on Days 56 and 84

Protocol follow-up procedures continue until day 112. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up

Group Type: EXPERIMENTAL

AlloStim

Intervention Type: BIOLOGICAL

AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.

Cryoablation

Intervention Type: PROCEDURE

Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance

Dosing Schedule B without cryoablation

The priming step with ID injections of AlloStim on Days 0, 3, 7, 10 and day 14

• IV AlloStim on Day 21
• The booster step with two IV booster infusions of AlloStim on Days 49 and 77

Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up

Group Type: EXPERIMENTAL

AlloStim

Intervention Type: BIOLOGICAL

AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.

Interventions

AlloStim

AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.

Intervention Type: BIOLOGICAL

Cryoablation

Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance

Intervention Type: PROCEDURE

Other Intervention Names

CryoVax

Eligibility Criteria

Inclusion Criteria

1. Adult males and female subjects aged 18-80 years at screening visit

2. Pathologically confirmed diagnosis of colorectal adenocarcinoma

3. Presenting with metastatic disease:

• Primary can be intact or previously resected
• Metastatic lesion(s) in liver must be non-resectable
• Extrahepatic disease acceptable

4. At least one liver lesion able to be visualized by ultrasound and determined to be safely assessable for percutaneous cryoablation

5. Previous treatment failure of two previous lines of active systemic chemotherapy:

• Previous chemotherapy must have included an oxaliplatin-containing (e.g. FOLFOX) and an irinotecan-containing (e.g. FOLFIRI) regimen
• with or without bevacizumab
• administered in adjuvant setting or for treatment of metastatic disease
• If KRAS wild type, must have at least one prior anti-EGFR therapy
• Treatment failure can be due to disease progression or toxicity
• Disease progression on second line therapy must be documented radiologically and must have occurred during or within 30 days following the last administration of treatment for metastatic disease

6. ECOG performance score: 0-1

7. Adequate hematological function:

• Absolute granulocyte count ≥ 1,200/mm3
• Platelet count ≥ 100,000/mm3
• PT/INR ≤ 1.5 or correctable to <1.5 at time of interventional procedures
• Hemoglobin ≥ 9 g/dL (may be corrected by transfusion)

8. Adequate Organ Function:

• Creatinine ≤ 1.5 mg/dL
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 2.5 times ULN
• Aspartate aminotransferase (AST) or (SGOT) ≤ 2.5 times ULN
• Alanine aminotransferase (ALT) or (SGPT) ≤ 2.5 times ULN

9. EKG without clinically relevant abnormalities

10. Female subjects: Not pregnant or lactating

11. Patients with child bearing potential must agree to use adequate contraception

12. Study specific informed consent in the native language of the subject.

Exclusion Criteria

1. Bowel obstruction or high risk for obstruction

2. Moderate or severe ascites requiring medical intervention

3. Clinical evidence or radiological evidence of brain metastasis or leptomeningeal involvement

4. Symptomatic asthma or COPD

5. Pulmonary lymphangitis or symptomatic pleural effusion (grade ≥ 2) that results in pulmonary dysfunction requiring active treatment or oxygen saturation <92% on room air

6. Bevacizumab (Avastin®) treatment within 6 weeks of scheduled cryoablation procedure

7. Regorafenib prior to the Study Period

8. Taking anticoagulant medication for concomitant medical condition (unless can be safely discontinued for invasive cryoablation, biopsy and intratumoral injection procedures)

9. Prior allogeneic bone marrow/stem cell or solid organ transplant

10. Chronic use (> 2 weeks) of greater than physiologic doses of a corticosteroid agent (dose equivalent to > 5 mg/day of prednisone) within 30 days of the first day of study drug treatment

• Topical corticosteroids are permitted

11. Prior diagnosis of an active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, autoimmune thyroid disease, uveitis). Well controlled Type I diabetes allowed

12. Prior experimental therapy

13. History of blood transfusion reactions

14. Known allergy to bovine products

15. Progressive viral or bacterial infection

• All infections must be resolved and the subject must remain afebrile for seven days without antibiotics prior to being placed on study

16. Cardiac disease of symptomatic nature

17. History of HIV positivity or AIDS

18. Concurrent medication known to interfere with platelet function or coagulation (e.g., aspirin, ibuprofen, clopidogrel, or warfarin) unless such medications can be discontinued for an appropriate time period based on the drug half-life and known activity (e.g., aspirin for 7 days) prior to cryoablation and biopsy procedures

19. History of severe hypersensitivity to monoclonal antibody drugs or any contraindication to any of the study drugs

20. Psychiatric or addictive disorders or other condition that, in the opinion of the investigator, would preclude study participation.

21. Subjects that lack ability to provide consent for themselves

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mirror Biologics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Madappa Kundranda, MD PHD

Role: PRINCIPAL_INVESTIGATOR

Banner MD Anderson Cancer Center

Locations

Banner MD Anderson Medical Center

Gilbert, Arizona, United States

Countries

United States

References

Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C, Olver CS, Lencioni AM, Dusto NL, Tal A, Har-Noy M, Lillehei KO, Katsanis E, Graner MW. Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. Int J Hyperthermia. 2013 Aug;29(5):390-8. doi: 10.3109/02656736.2013.800997. Epub 2013 Jun 20.

Reference Type: BACKGROUND

PMID: 23786302 (View on PubMed)

Mayer-Sonnenfeld T, Har-Noy M, Lillehei KO, Graner MW. Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure. Int J Hyperthermia. 2013 Sep;29(6):520-7. doi: 10.3109/02656736.2013.796529. Epub 2013 Jun 4.

Reference Type: BACKGROUND

PMID: 23734882 (View on PubMed)

LaCasse CJ, Janikashvili N, Larmonier CB, Alizadeh D, Hanke N, Kartchner J, Situ E, Centuori S, Har-Noy M, Bonnotte B, Katsanis E, Larmonier N. Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-gamma-dependent mechanism. J Immunol. 2011 Dec 15;187(12):6310-7. doi: 10.4049/jimmunol.1101812. Epub 2011 Nov 9.

Reference Type: BACKGROUND

PMID: 22075702 (View on PubMed)

Janikashvili N, LaCasse CJ, Larmonier C, Trad M, Herrell A, Bustamante S, Bonnotte B, Har-Noy M, Larmonier N, Katsanis E. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. Blood. 2011 Feb 3;117(5):1555-64. doi: 10.1182/blood-2010-06-288621. Epub 2010 Dec 1.

Reference Type: BACKGROUND

PMID: 21123824 (View on PubMed)

Har-Noy M, Zeira M, Weiss L, Fingerut E, Or R, Slavin S. Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma. Leuk Res. 2009 Apr;33(4):525-38. doi: 10.1016/j.leukres.2008.08.017. Epub 2008 Oct 1.

Reference Type: BACKGROUND

PMID: 18834631 (View on PubMed)

Har-Noy M, Zeira M, Weiss L, Slavin S. Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity. Leuk Res. 2008 Dec;32(12):1903-13. doi: 10.1016/j.leukres.2008.05.007. Epub 2008 Jun 18.

Reference Type: BACKGROUND

PMID: 18565579 (View on PubMed)

Har-Noy M, Slavin S. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement? Med Hypotheses. 2008;70(6):1186-92. doi: 10.1016/j.mehy.2007.10.008. Epub 2007 Dec 3.

Reference Type: BACKGROUND

PMID: 18054441 (View on PubMed)

Zeng Y, Stokes J, Hahn S, Hoffman E, Katsanis E. Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD. Bone Marrow Transplant. 2014 Aug;49(8):1076-83. doi: 10.1038/bmt.2014.91. Epub 2014 Apr 28.

Reference Type: BACKGROUND

PMID: 24777185 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

ITL-019-CORK-CRYVAC

Identifier Type: -

Identifier Source: org_study_id